Abstract
Background: Elzovantinib is a novel, type I tyrosine kinase inhibitor (TKI) that targets MET, SRC, and CSF1R. Genetic alterations in MET, including exon 14 skipping (Δex14) mutations and other oncogenic mutations, amplifications, and fusions are present in many tumor types. The Phase 1 SHIELD-1 trial (NCT03993873) is evaluating safety, pharmacokinetics (PK), and preliminary activity of elzovantinib in patients (pts) with advanced solid tumors harboring genetic MET alterations. An early analysis included 46 efficacy evaluable pts.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call